Advancing Healthcare Narratives
with
Expertise and Precision
KCSA’s Healthcare Practice understands the challenges faced by life sciences companies, particularly those in clinical stages with limited news flow. Our strategy addresses this by leveraging targeted public relations to help your brand maintain visibility and investor interest during critical periods to bring attention to your innovation. We develop comprehensive communication plans that integrate public relations, investor relations, and social media, ensuring consistent and impactful messaging across all platforms.
Our team excels in translating complex medical and scientific information into accessible content, facilitating engagement with media, investors, and the broader healthcare community. By positioning clients as thought leaders and experts within their therapeutic areas, we enhance their profiles and support their business objectives. Our proactive approach ensures that clients remain at the forefront of industry conversations, attracting the attention of key stakeholders and potential partners.
Innovation deserves attention.
— Help your science speak to investors, media, and the world.
Key Capabilities
- Media Training
- Social Listening & Analytics
- Data Storytelling
- Crisis Management
- Media Training
- Video Production
- Regulatory/Scientific Communications
- Content Creation
- Pitching
- Reporter intros
- Conferences
- KOL & Advocacy Engagement
- NewsJacking
- Press Releases
- Proactive Media Relations
- Integrated Campaign Planning
- Thought Leadership
- Expert Sourcing
- Byline Development
Key Capabilities
- Media Training
- Social Listening & Analytics
- Data Storytelling
- Crisis Management
- Video Production
- Regulatory/Scientific Communications
- Content Creation
- Pitching
- Reporter intros
- Conferences
- KOL & Advocacy Engagement
- NewsJacking
- Press Releases
- Proactive Media Relations
- Integrated Campaign Planning
- Thought Leadership
- Expert Sourcing
- Byline Development
Industry Insights
The global biotechnology market is projected to grow from $1.55 trillion in 2024 to $4.25 trillion by 2034, reflecting a CAGR of 10.8% over the forecast period.
In 2024, the U.S. biotechnology market was valued at $246.18 billion and is anticipated to reach $763.82 billion by 2033, growing at a CAGR of 11.9%.
The global clinical trials market reached $83.75 billion in 2024 and is projected to hit around $149.58 billion by 2034, growing at a CAGR of 6.1% from 2025 to 2034.
In 2024, there were 7,089 clinical trial completions, surpassing the 6,234 trials completed in 2023, with Phase I studies accounting for 40.92% of the completions.
The biotechnology industry recorded 57,000 funding rounds in 2024, with an average investment of $45.3 million, driving advancements in medical and technological solutions.
In 2024, venture capital investment in U.S. and European biotech companies increased to $28.1 billion, up from $21.2 billion in the previous year.